Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by davgroon Mar 09, 2023 4:20pm
188 Views
Post# 35329075

ATE Closes @ C$ 0.48 - Lowest Close Since Tax Loss Selling

ATE Closes @ C$ 0.48 - Lowest Close Since Tax Loss SellingATE's stock price is getting closer to my target for restarting a long position which is C$ 0.45.  I Sold my entire ATE position on January 17th @ C$ 0.64 (average) for a respectable 33% return.  I have been sitting on the sidelines ever since just watching trading activity and waiting for updates from the company.  Long term I believe this could be a homerun in the pain management market if the science holds true.  Right now it is just a waiting game for investors.

I have been saying for weeks that the stock will continue to drift lower with lack of news.  There has been no insider buying even at these low levels.  The Dumbster will try to convince you that management vesting their RSUs is insider buying....NOT.  In fact its the opposite as the FMV (fair market value) of their vested RSUs is included in their taxable annual income as the RSUs are strictly income compensation awarded to insiders in the form of stock.

Now if we see any SEDI reports of a "Public Market Buy" by insiders then I will have a different view of management's long term commitment to the science.

The Dumpster says he has put me on ignore (yeah right) but I will continue to fact check his misleading and erroneous posts. You will alwys be my favourite TROLL Dumpster !!

GLTA
<< Previous
Bullboard Posts
Next >>